

TMX JV 6/29/05 899-65892-02 401229 614

JC04 Rec'd PCT/PTO 01 JUL 2005

PCT

PATENT
Attorney Reference Number 899-65892-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heinrich et al.

Application No. 10/517,905

Filed: December 10, 2004

Confirmation No. 4619

For: ACTIVATING MUTATIONS OF
PLATELET DERIVED GROWTH
FACTOR RECEPTOR ALPHA (PDGFRA)
AS DIAGNOSTIC MARKERS AND
THERAPEUTIC TARGETS

Examiner: _____

Art Unit: _____

Attorney Reference No. 899-65892-02

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s) _____

Tanya M. Harding, Ph.D.

Date Mailed June 29, 2005

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

Information Disclosure Statement
 Form 1449 and 42 references cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By _____


Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing

Rec'd USPTO 01 JUL 2005

PATENT

#5



TMH-dv 06/29/05 899-65892-02 401225 614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heinrich et al.

Application No. 10/517,905

Filed: December 10, 2004

Confirmation No. 4619

For: ACTIVATING MUTATIONS OF
PLATELET DERIVED GROWTH
FACTOR RECEPTOR ALPHA (PDGFRA)
AS DIAGNOSTIC MARKERS AND
THERAPEUTIC TARGETS

Examiner: _____

Art Unit: _____

Attorney Reference No. 899-65892-02

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Tanya M. Harding, Ph.D.
June 29, 2005

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request. All other listed documents are enclosed.

Applicants are filing this Information Disclosure Statement ("IDS") before the mailing of a first Office action on the merits. It is believed that no fee is due to file this IDS. If the


Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



899-65892-02

Rec'd PTO 01 JUL 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	899-65892-02
	Application Number	10/517,905
	Filing Date	December 10, 2004
	First Named Inventor	Heinrich
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,194,158	Feb. 27, 2001	Kroes <i>et al.</i>
		6,291,661	Sep. 18, 2001	Graddis <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Abu-Duhier <i>et al.</i> , "FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group," <i>J. Haematol</i> 111(1):190 (October 2000)
		Abu-Duhier <i>et al.</i> , "Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia," <i>J. Haematol</i> 113(4):983-988 (June 2001)
		Al-Ali <i>et al.</i> , "High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib," <i>Hematol J.</i> 5(1):55-60 (2004)

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL 01 2005

PRAESIT & TRADES INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	899-65892-02
Application Number	10/517,905
Filing Date	December 10, 2004
First Named Inventor	Heinrich
Art Unit	
Examiner Name	

	Blanke <i>et al.</i> , "Evaluation of the Safety and Efficacy of an Oral Molecularly-Targeted Therapy, STI571, in Patients (Pts) with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GISTS) Expressing C-KIT (CD117)," <i>ASCO</i> , May 12-15, 2001 (<i>Meeting Abstract</i>)
	Borg <i>et al.</i> , "Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects," <i>J. Clinical. Investigation</i> 114(3):379-388 (August 2004)
	Chen <i>et al.</i> , "Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors," <i>J. Cancer</i> 105(1):130-135 (May 20, 2003)
	Corless <i>et al.</i> , "Biology of gastrointestinal stromal tumors," <i>J. Clin. Oncol.</i> 22(18):3813-3825 (September 15, 2004)
	Debiec-Rychter <i>et al.</i> , "Use of c-KIT/PDGFR α mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered in phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group," <i>Eur J Cancer</i> , 40(5):689-95 (March 2004)
	Demetri, "Targeting c-kit Mutations in Solid Tumors: Scientific Rationale and Novel Therapeutic Options," <i>Semin Oncol.</i> 5 Suppl 17:19-26 (October 2001)
	Demetri <i>et al.</i> , "Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: intergroup S0033 early results," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)
	Duensing <i>et al.</i> , "Protein Kinase C theta (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTS)," <i>Cancer Res.</i> 64(15):5127-5131 (August 1, 2004)
	Fenski <i>et al.</i> , "Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells," <i>J. Haematol</i> 108(2):322-330 (February 2000)
	Gari <i>et al.</i> , "c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia," <i>J. Haematol</i> 105(4):894-900 (June 1999)
	Griswold <i>et al.</i> , "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis," <i>Blood</i> 104(9):2912-2918 (July 8, 2004)
	Heinrich <i>et al.</i> , "Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations," <i>Hum. Pathol.</i> 33(5):484-95 (May 2002)
	Heinrich <i>et al.</i> , "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor," <i>Blood</i> 96(3):925-932 (August 1, 2000)
	Heinrich <i>et al.</i> , "Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies," <i>J. Clinical Oncology</i> 20(6):1692-1703 (March 15, 2002)

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL 01 2005

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

		Attorney Docket Number Application Number Filing Date First Named Inventor Art Unit Examiner Name	899-65892-02 10/517,905 December 10, 2004 Heinrich
		Heinrich <i>et al.</i> , "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor," <i>J. Clin Oncol.</i> 21(23):4342-4349 (December 1, 2003)	
		Heinrich <i>et al.</i> , "KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs)," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)	
		Heinrich <i>et al.</i> , "Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas," <i>Cancer Treatment Res.</i> 120:129-150 (2004)	
		Heinrich <i>et al.</i> , "PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors," <i>Science</i> 299:708-710 (January 31, 2003)	
		Hirota <i>et al.</i> , "Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours," <i>J Pathol.</i> 193(4):505-510 (April 2001)	
		Hochhaus <i>et al.</i> , "Interim analysis of imatinib treatment in 300 patients with chronic myelogenous leukemia (CML): evaluation of response and resistance," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)	
		Joensuu <i>et al.</i> , "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor," <i>N Engl J Med</i> 344(14):1052-1056 (April 5, 2001)	
		Joensuu <i>et al.</i> , "Gastrointestinal stromal tumor (GIST) patients who respond to imatinib (STI571, Gleevec) show marked decline of circulating levels of VEGF, KIT, and bFGF in serum, but not stem cell factor (SCF) levels," <i>ASCO</i> , May 18-21, 2002 (<i>Meeting Abstract</i>)	
		Johnson <i>et al.</i> , "Phase II study of STI571 (Gleevec™) for patients with small cell lung cancer," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)	
		Kubota <i>et al.</i> , "Chemosensitivity of gastric cancer detected by cDNA microarray," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)	
		Madani <i>et al.</i> , "Expression of KIT and epidermal growth factor receptor (EGFR) in chemotherapy refractory non-seminomatous germ cell tumors (GCT)," <i>ASCO</i> May 28-21, 2002 (<i>Meeting Abstract</i>)	
		Medeiros <i>et al.</i> , "KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications," <i>Am J. Surg Pathol.</i> 28(7):889-894 (July 2004)	
		Nakamura <i>et al.</i> , "Abnormalities of the p53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes," <i>J. Nippon Med Sch</i> 68(2):143-148 (April 2001) (<i>English Abstract Only</i>)	
		O'Farrell <i>et al.</i> , "Analysis of mechanism of action and biomarkers for kinase inhibitor SU5416 in AML patients," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)	

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL 01 2005

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	899-65892-02
Application Number	10/517,905
Filing Date	December 10, 2004
First Named Inventor	Heinrich
Art Unit	
Examiner Name	

	O'Farrell <i>et al.</i> , "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo," <i>Blood</i> 101(9):3597-3605 (May 1, 2003)
	Rubin <i>et al.</i> , "KIT Activation is a Ubiquitous Feature of Gastrointestinal Stromal Tumors," <i>Cancer Research</i> 61:8118-8121 (November 15, 2001)
	Singer <i>et al.</i> , "Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors," <i>J. Clinical Oncology</i> 20(18):3898-3905 (September 15, 2002)
	Subramanian <i>et al.</i> , "Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles," <i>Oncogene</i> 23(47):7780-7790 (October 14, 2004)
	van Oosterom <i>et al.</i> , "Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study," <i>Lancet</i> 358(9291):1421-1423 (October 27, 2001)
	van Oosterom <i>et al.</i> , "ST1571, an Active Drug in Metastatic Gastro Intestinal Stromal Tumors (GIST), an EORTC Phase I Study," <i>ASCO</i> May 12-15, 2001 (<i>Meeting Abstract</i>)
	von Mehren <i>et al.</i> , "High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs)," <i>ASCO</i> May 18-21, 2002 (<i>Meeting Abstract</i>)
	"Gleevec™ Shows Promise for Type of Gastrointestinal Tumor," <i>National Cancer Institute - Clinical Trial Results</i> http://www.cancer.gov/clinicaltrials/results/gleevec-shows-promise0202 , posted 7/20/2001; printed 2/26/2005
	Homo sapiens platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), mRNA, Locus ID: XM_011186, PRI 07-Feb-2002, NCBI, printed 4/18/02
	Human DNA for alpha-platelet-derived growth factor receptor, exon 1, Locus ID: D50001S01, PRI 14-Apr-2000, NCBI, printed 6/5/2002
	PDGFRA: platelet-derived growth factor receptor, alpha polypeptide, Locus ID: 5156, NCBI, printed 6/5/2002

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.